Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
作者： Eduardo F. Mysler , Alberto J. Spindler , Renato Guzman , Marc Bijl , David Jayne
DOI: 10.1002/ART.38037
关键词:
摘要: Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15, followed by a single infusion at week 16 and every 16 weeks thereafter, accompanied by background glucocorticoids plus either mycophenolate mofetil (MMF) or the Euro‐Lupus Nephritis Trial (ELNT) regimen (cyclophosphamide followed by azathioprine). The study was …
core.ac.uk
sci-hub.se 参考文章(29)
Bevra H. Hahn, Maureen A. McMahon, Alan Wilkinson, W. Dean Wallace, David I. Daikh, John D. FitzGerald, George A. Karpouzas, Joan T. Merrill, Daniel J. Wallace, Jinoos Yazdany, Rosalind Ramsey-Goldman, Karandeep Singh, Mazdak Khalighi, Soo-In Choi, Maneesh Gogia, Suzanne Kafaja, Mohammad Kamgar, Christine Lau, William J. Martin, Sefali Parikh, Justin Peng, Anjay Rastogi, Weiling Chen, Jennifer M. Grossman, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Arthritis Care and Research. ,vol. 64, pp. 797- 808 ,(2012) , 10.1002/ACR.21664
P. P. Tak, P. J. Mease, M. C. Genovese, J. Kremer, B. Haraoui, Y. Tanaka, C. O. Bingham, A. Ashrafzadeh, H. Travers, S. Safa-Leathers, S. Kumar, W. Dummer, Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial Arthritis & Rheumatism. ,vol. 64, pp. 360- 370 ,(2012) , 10.1002/ART.33353
Brad H Rovin, Richard Furie, Kevin Latinis, R John Looney, Fernando C Fervenza, Jorge Sanchez‐Guerrero, Romeo Maciuca, David Zhang, Jay P Garg, Paul Brunetta, Gerald Appel, LUNAR Investigator Group, None, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study† Arthritis & Rheumatism. ,vol. 64, pp. 1215- 1226 ,(2012) , 10.1002/ART.34359
VandanaD Pradhan, ManishaM Patwardhan, Kanjaksha Ghosh, Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Indian Journal of Dermatology, Venereology and Leprology. ,vol. 76, pp. 145- ,(2010) , 10.4103/0378-6323.60558
Cándido Díaz-Lagares, Sara Croca, Shirish Sangle, Edward M Vital, Fausta Catapano, Agustín Martínez-Berriotxoa, Francisco García-Hernández, José-Luis Callejas-Rubio, Javier Rascón, David D'Cruz, David Jayne, Guillermo Ruiz-Irastorza, Paul Emery, David Isenberg, Manuel Ramos-Casals, Munther A Khamashta, UK The, Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmunity Reviews. ,vol. 11, pp. 357- 364 ,(2012) , 10.1016/J.AUTREV.2011.10.009
W. Rigby, H.-P. Tony, K. Oelke, B. Combe, A. Laster, C. A. von Muhlen, E. Fisheleva, C. Martin, H. Travers, W. Dummer, Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial† Arthritis & Rheumatism. ,vol. 64, pp. 350- 359 ,(2012) , 10.1002/ART.33317
FA Houssiau, EM Ginzler, Current treatment of lupus nephritis. Lupus. ,vol. 17, pp. 426- 430 ,(2008) , 10.1177/0961203308090029
Mark C. Genovese, Jeffrey L. Kaine, Mitchell B. Lowenstein, José Del Giudice, Andrew Baldassare, Joy Schechtman, Edward Fudman, Michael Kohen, Sheila Gujrathi, Robert G. Trapp, Nadera J. Sweiss, Greg Spaniolo, Wolfgang Dummer, , Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis & Rheumatism. ,vol. 58, pp. 2652- 2661 ,(2008) , 10.1002/ART.23732
David S. Pisetsky, Anti-DNA and autoantibodies Current Opinion in Rheumatology. ,vol. 12, pp. 364- 368 ,(2000) , 10.1097/00002281-200009000-00002
Melissa R. Arbuckle, Micah T. McClain, Mark V. Rubertone, R. Hal Scofield, Gregory J. Dennis, Judith A. James, John B. Harley, Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England Journal of Medicine. ,vol. 349, pp. 1526- 1533 ,(2003) , 10.1056/NEJMOA021933